̶ Exelixis will make upfront payment and contribute research funding for option to in-license at Investigational New Drug (IND) filing ̶ ALAMEDA, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)- ...

- Lantern will evaluate and potentially develop ADC programs with novel patent protected linkers, drug payloads and conjugation processes from Califia that have demonstrated enhanced, highly targeted ...

- Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia - Actimab-A selected for National Cancer Institute's recently opened ...

ZURICH, SWITZERLAND, May 5, 2025 --VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.

NextCure (NASDAQ:NXTC) stock fell nearly 20% Thursday following news that it was shifting resources from its drug candidate NC762 to its antibody drug conjugate program. The biotech company said that ...

CHEYNEY, Pa., March 28, 2022 /PRNewswire/ -- Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, will be presenting new preclinical ...

VERAXA Biotech AG, a developer of innovative cancer therapies, has announced a partnership with OmniAb, Inc. to create a bispecific antibody drug conjugate (bsADC) program aimed at treating solid ...

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced that is has exercised its first of five exclusive, target-specific options with LegoChem Biosciences (LCB, ...